Pembrolizumab for the treatment of non-small-cell lung cancer.

By E. Garon, N. Rizvi, R. Hui, N. Leighl, A. Balmanoukian, J. Eder, A. Patnaik, C. Aggarwal, M. Gubens, L. Horn and 17 more. New England Journal of Medicine, 2015

5,466 citations recorded by the source corpus.

Subfields: Biotechnology, Oncology

View Paper: https://www.semanticscholar.org/paper/3d53f102547cbf9cd0633a867931b7067399d294

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Wolchok
2. D. Pardoll
3. Antoni Ribas
4. F. Hodi
5. M. Postow
6. G. Dranoff
7. Razelle Kurzrock
8. G. Freeman

Citations in the corpus

• Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers (2017, background): “For example, response rates to single-agent PD-1/PD-L1 inhibition in patients with melanoma, non–small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) are 40% (1, 10), 25% (2, 3), and 19% (4), respectively.”
• Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. (2020, background): “89], respectively) was notable, particularly because patients with PD-L1 TPS, 1%have a lower chance of benefit with single-agent anti‒PD-1 therapy.(1,3,15,16) In addition, survival was improved with the addition of pembrolizumab to chemotherapy in patients with PD-L1 TPS 1%-49%.”
• PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression (2017, neutral): “Clin Cancer Res; 23(14) July 15, 2017 Clinical Cancer Research 3718 Jiao et al.”
• Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. (2016, background): “AKT/mTOR activation was detected in adenocarcinoma and squamous cell carcinoma cell lines with mutations in NRAS (H1299), KRAS (H157/A549), EGFR (H1975/H1650), BRAF (H2087), PIK3CA (H1650), EML4-ALK (H3122), RET (H1563), autocrine productionof FGF2 (H226), or FGFR1 amplification (H520; Fig.”
• Cooperation between Constitutive and Inducible Chemokines Enables T-cell Engraftment and Immune Attack in Solid Tumors (2019, background): “Moreover, TILs activation by immune modulation can lead to eradication of human tumors in the context of adoptive T-cell therapy (Dudley et al., 2002; Garon et al., 2015; Postow et al., 2015; Wolchok et al., 2013).”
• Acquired Resistance to Immune Checkpoint Inhibitors (2020, background): “PD-L1 expression, tumor mutational burden, tumor infiltrating lymphocytes (TILs) or related gene expression signatures have been explored as potential predictors and various other markers are currently under investigation (Chen et al., 2016; Cristescu et al., 2018; Garon et al., 2015; Hugo et al., 2”